Pfizer Remains Flexible On Consumer Health In Restructuring
Executive Summary
The adage "the more things change, the more they stay the same" may come to mind for Pfizer's consumer business: it will be a standalone division as part of a restructuring that takes effect in January but it's still for sale.
You may also be interested in...
10 Things For Pfizer's New CEO To Worry About
Albert Bourla will face opportunities and potential pitfalls.
Pfizer Deals Consumer Health Its Own Hand, Plays Waiting Game For Bids
By setting up Pfizer Consumer Healthcare to have sales and earnings results reported separately, pharma giant could be making the division's assets more visible to potential buyers. Its sales pitch: "With a strong portfolio of global brands that span health and wellness, the company believes this business is well positioned to continue its growth."
Pfizer Plays Up Its In-house Potential, Avoids M&A Talk
Pfizer execs say they are focused on commercial execution and pipeline development to drive growth. No viable buyer has emerged for the consumer business, CEO Read said.